Welcome to the Grey Highway research guides — detailed, evidence-based comparisons and analyses designed to support research literacy in the Australian peptide and GLP-1 space.
Whether you’re comparing dual agonists against triple agonists, weighing tissue repair peptides, or navigating Australia’s complex TGA framework, these guides provide the foundational knowledge researchers need.
Available Guides
Retatrutide vs Tirzepatide: Research Comparison — How does the investigational triple GIP/GLP-1/glucagon agonist stack up against tirzepatide in preclinical and clinical data?
BPC-157 vs TB-500: Tissue Repair Research Compared — A head-to-head look at two of the most researched tissue repair peptides in preclinical literature.
Ozempic vs Wegovy vs Mounjaro in Australia: What Researchers Need to Know — Breaking down the branded research compounds, their active ingredients, TGA status, and key research differences.
Semaglutide vs Tirzepatide: GLP-1 Research Compared — Single-target GLP-1 receptor agonism vs dual GIP/GLP-1 agonism: what the published research shows.
Are Peptides Legal in Australia? TGA Regulations Explained — A comprehensive look at Australia’s regulatory framework for peptide research compounds, TGA scheduling, and import rules.
All guides are for educational and research literacy purposes only. Grey Highway does not provide medical or therapeutic advice. Join our Telegram community to discuss research with fellow Australian researchers.